AbbVie plans to build out its presence in obesity market [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
treatments, leaning on the weight-loss drug it licensed ?last year from Danish biotech Gubra. Gubra's drug, GUBamy, mimics the hormone amylin and could ?be used as an alternative to popular GLP-1 drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound to help people lose more weight with fewer side effects. AbbVie is focusing on "tolerability and durability of weight loss for ?patients that tend to ?cycle off of these first-gen therapies," chief medical officer Roopal Thakkar said at the J.P. Morgan Healthcare Conference. "We ?have the longer acting amylin. We like the tolerability profile of that mechanism, but we are interested in building that out further," added Thakkar. GLP-1 drugs such ?as Wegovy and Zepbound mimic hormones produced in the gut, boosting ?insulin release, slowing digestion and promoting feelings of fullness. Amylin-based drugs replicate a pancreas-derived hormone that also delays gastric emptying and suppresses appetite. Early data suggests that amyli
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- ASML Soars Above $500 Billion Value on TSMC's Upbeat Outlook [Yahoo! Finance]Yahoo! Finance
- JPM26: Novo Nordisk reshapes its strategy under new CEO [Yahoo! Finance]Yahoo! Finance
- Eli Lilly: Sell It And Buy Novo Nordisk Instead [Seeking Alpha]Seeking Alpha
- Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk to Keep Pursuing Deals to Expand Obesity Portfolio, CEO Says [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website